Regeneron Logo.jpg
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
December 07, 2024 19:00 ET | Regeneron Pharmaceuticals, Inc.
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate...
ADPT new logo.jpg
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
December 07, 2024 18:30 ET | Adaptive Biotechnologies
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment...
YmAbs_Logo_RGB.jpg
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET | Y-mAbs Therapeutics, Inc.
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
BeamLogo_Color_CMYK.jpg
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
December 07, 2024 11:30 ET | Beam Therapeutics
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety...
Merus logo 300dpi_.jpg
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
December 07, 2024 01:30 ET | Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...
Hut8_logo_black_horizontal.jpg
2024年11月のハット8 (Hut 8) 運営アップデート
December 06, 2024 23:38 ET | Hut 8 Corp.
マイニングでは21.0 EH/sおよび967 MW1、2を管理、約35 EH/sへの道筋 マイアミ発 , Dec. 07, 2024 (GLOBE NEWSWIRE) -- 大規模エネルギー・インフラストラクチャの大手垂直統合オペレーターであり、北米最大のビットコイン・マイナーの1つであるハット8コーポレーション (Hut 8 Corp.) (NASDAQ | TSX: HUT)...
Athira Pharma Logo RGB_300ppi.jpg
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
December 06, 2024 17:30 ET | Athira Pharma, Inc.
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
Tandy Logo_Slate.png
Tandy Leather Factory Announces Agreement to Sell Headquarters Facilities
December 06, 2024 17:15 ET | Tandy Leather Factory, Inc.
FORT WORTH, Texas, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (the “Company”, Nasdaq: TLF) today announced that it had signed a Purchase and Sale Agreement to sell its corporate...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Organizational Changes
December 06, 2024 17:00 ET | Zevra Therapeutics
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment...
Logo.png
Globalink Investment Inc. Announces Charter and Trust Agreement Amendments
December 06, 2024 17:00 ET | Globalink Investment Inc.
New York, NY, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Globalink Investment Inc. (Nasdaq: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today...